ITOS iTeos Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ITOS

Price (delayed)

$10.57

Market cap

$378.86M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.15

Enterprise value

$133.47M

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of ...

Highlights
iTeos Therapeutics's gross profit has plunged by 95% YoY and by 81% from the previous quarter
ITOS's revenue has dropped by 95% year-on-year and by 81% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://iteostherapeutics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of ITOS
Market
Shares outstanding
35.84M
Market cap
$378.86M
Enterprise value
$133.47M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.66
Price to sales (P/S)
30.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.6
Earnings
Revenue
$12.6M
EBIT
-$109.03M
EBITDA
-$108.13M
Free cash flow
-$106.72M
Per share
EPS
-$3.15
Free cash flow per share
-$2.98
Book value per share
$16.07
Revenue per share
$0.35
TBVPS
$18.67
Balance sheet
Total assets
$667.59M
Total liabilities
$92.36M
Debt
$6.06M
Equity
$575.23M
Working capital
$510.64M
Liquidity
Debt to equity
0.01
Current ratio
13.76
Quick ratio
13.3
Net debt/EBITDA
2.27
Margins
EBITDA margin
-858.5%
Gross margin
100%
Net margin
-894.3%
Operating margin
-1,199.7%
Efficiency
Return on assets
-16.2%
Return on equity
-18.4%
Return on invested capital
-24.5%
Return on capital employed
-17.4%
Return on sales
-865.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ITOS stock price

How has the iTeos Therapeutics stock price performed over time
Intraday
-3.82%
1 week
-1.03%
1 month
-5.54%
1 year
-21.24%
YTD
-3.47%
QTD
-22.51%

Financial performance

How have iTeos Therapeutics's revenue and profit performed over time
Revenue
$12.6M
Gross profit
$12.6M
Operating income
-$151.1M
Net income
-$112.64M
Gross margin
100%
Net margin
-894.3%
iTeos Therapeutics's gross profit has plunged by 95% YoY and by 81% from the previous quarter
ITOS's revenue has dropped by 95% year-on-year and by 81% since the previous quarter
The company's net income has shrunk by 83% QoQ
The operating income has shrunk by 62% QoQ

Growth

What is iTeos Therapeutics's growth rate over time

Valuation

What is iTeos Therapeutics stock price valuation
P/E
N/A
P/B
0.66
P/S
30.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.6
The EPS has dropped by 83% since the previous quarter
ITOS's equity is down by 13% YoY and by 3.9% from the previous quarter
ITOS's P/B is 6% below its last 4 quarters average of 0.7
The P/S is 159% higher than the last 4 quarters average of 11.6
ITOS's revenue has dropped by 95% year-on-year and by 81% since the previous quarter

Efficiency

How efficient is iTeos Therapeutics business performance
The ROIC has dropped by 105% year-on-year and by 93% since the previous quarter
The ROE has plunged by 90% from the previous quarter
The ROA has plunged by 88% from the previous quarter

Dividends

What is ITOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ITOS.

Financial health

How did iTeos Therapeutics financials performed over time
The quick ratio is down by 37% QoQ and by 9% YoY
The current ratio has declined by 37% since the previous quarter and by 8% year-on-year
iTeos Therapeutics's debt is 99% lower than its equity
iTeos Therapeutics's debt has increased by 30% YoY and by 2.2% QoQ
ITOS's equity is down by 13% YoY and by 3.9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.